E
Eikonizo Therapeutics
Biotech & Life Sciences · Cambridge, United States · Founded 2017
Developing therapies to improve the treatment of human disease, specifically neurodegenerative diseases MoreLess
Eikonizo Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. The company specializes in creating brain-penetrant small molecules that inhibit HDAC6, an enzyme implicated in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). By targeting HDAC6, Eikonizo aims to preserve axonal transport and reduce protein aggregates, thereby slowing or halting disease progression. Eikonizo operates in the biopharmaceutical market, serving patients suffering from neurodegenerative disorders. The company's business model revolves around research and development (R&D) of novel therapeutics, which are then brought to market through clinical trials and regulatory approval processes. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved therapies. Keywords: neurodegenerative, HDAC6 inhibitor, brain-penetrant, ALS, Alzheimer's, axonal transport, protein aggregates, biopharmaceutical, R&D, therapeutic development.
Company overview
Eikonizo Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Cambridge, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 71.3
Valuation & funding
Eikonizo Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Dec 2024 | $0 | — | Novo Nordisk | ↗ |
| SERIES A✓Equity / VC | Dec 2023 | $40M | $160M | Undisclosed | ↗ |
| GRANT✓Other financing | Mar 2020 | $500K | — | The Rainwater Charitable Foundation · Alzheimer’s Association | ↗ |
| DEBT✓Debt | May 2018 | $186K | — | Undisclosed | ↗ |
| EARLY VC✓Equity / VC | May 2018 | $186K | $743K | Undisclosed | ↗ |
| SEED✓Equity / VC | Apr 2018 | Undisclosed | ↗ | ||
| SPINOUT✓Other financing | Apr 2017 | Massachusetts General Hospital · Harvard Medical School | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 13 |
| 2025 | 14 |
| 2024 | 15 |
| 2023 | 11 |
| 2022 | 14 |
| 2021 | 11 |
Growth signals
Eikonizo Therapeutics website traffic
Latest recorded traffic for Eikonizo Therapeutics is 30 monthly website visits, down 76.9% over the last three months. Eikonizo Therapeutics's team declined 7.1% over the past year.
Comparisons
Eikonizo Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Eikonizo Therapeutics's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Eikonizo Therapeutics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Eikonizo Therapeutics has talent and traffic
team presence
In the news
Latest news about Eikonizo Therapeutics
Recent press, funding announcements, and product moves mentioning Eikonizo Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Eikonizo Therapeutics
An AI-synthesized read of the highest-engagement posts about Eikonizo Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Eikonizo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.